Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase 1/2a clinical trial to treat liver diseases; ARO-ENaC, which is in a Phase 1/2a clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-C3 for the treatment of complement-mediated disease that is in Phase 1/2a clinical trial; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH to treat uncontrolled gout; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase 1b clinical trial to treat clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.
Over the last 12 months, insiders at Arrowhead Pharmaceuticals, Inc. have bought $82,990 and sold $12.11M worth of Arrowhead Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Arrowhead Pharmaceuticals, Inc. have bought $77,792 and sold $26.92M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Lu Hongbo (director) — $165,980.
The last purchase of 1,000 shares for transaction amount of $27,500 was made by Lu Hongbo (director) on 2024‑03‑20.
2024-05-02 | Sale | Vakiener Victoria | director | 1,799 0.0014% | $23.31 | $41,935 | +2.80% | |
2024-04-01 | Sale | Hamilton James C | Chief Discovery/Trans Medicine | 6,000 0.0048% | $28.03 | $168,180 | -12.57% | |
2024-03-20 | Lu Hongbo | director | 1,000 0.0008% | $27.50 | $27,500 | -11.91% | ||
2024-03-19 | Lu Hongbo | director | 1,000 0.0008% | $28.00 | $28,000 | -10.45% | ||
2024-03-18 | Lu Hongbo | director | 1,000 0.0008% | $27.49 | $27,490 | -11.59% | ||
2024-03-06 | Sale | Myszkowski Kenneth Allen | Chief Financial Officer | 40,000 0.0323% | $35.19 | $1.41M | -29.36% | |
2024-01-31 | Sale | Anzalone Christopher Richard | Chief Executive Officer | 57,499 0.0525% | $32.35 | $1.86M | -19.70% | |
2024-01-12 | Sale | Hamilton James C | Chief Discovery/Trans Medicine | 7,940 0.0075% | $36.89 | $292,904 | -27.47% | |
2024-01-11 | Sale | GIVEN DOUGLAS B | director | 2,911 0.0028% | $38.06 | $110,788 | -29.51% | |
2024-01-11 | Sale | Ferrari Mauro | director | 3,147 0.003% | $38.06 | $119,787 | -29.51% | |
2024-01-11 | Sale | Waddill William D. | director | 3,934 0.0037% | $38.07 | $149,759 | -29.51% | |
2024-01-11 | Sale | Vakiener Victoria | director | 4,720 0.0045% | $38.10 | $179,813 | -29.51% | |
2024-01-05 | Sale | O'Brien Patrick | COO and General Counsel | 22,841 0.021% | $35.27 | $805,716 | -23.80% | |
2024-01-05 | Sale | Myszkowski Kenneth Allen | Chief Financial Officer | 16,104 0.0148% | $35.27 | $567,910 | -23.80% | |
2024-01-05 | Sale | Hamilton James C | 32,143 0.0295% | $35.18 | $1.13M | -23.80% | ||
2024-01-05 | Sale | San Martin Javier | Chief Medical Officer | 8,303 0.0076% | $35.26 | $292,804 | -23.80% | |
2024-01-05 | Sale | Oliver Tracie | Chief Commercial Officer | 74 <0.0001% | $33.89 | $2,508 | -23.80% | |
2024-01-04 | Sale | O'Brien Patrick | COO and General Counsel | 1,600 0.0014% | $32.63 | $52,208 | -20.56% | |
2024-01-03 | Sale | O'Brien Patrick | COO and General Counsel | 8,749 0.0082% | $32.28 | $282,439 | -13.66% | |
2024-01-03 | Sale | Hamilton James C | 6,300 0.0059% | $32.19 | $202,781 | -13.66% |
Anzalone Christopher Richard | Chief Executive Officer | 3715048 2.9985% | $26.26 | 4 | 35 | <0.0001% |
O'Brien Patrick | COO and General Counsel | 464385 0.3748% | $26.26 | 0 | 11 | |
Myszkowski Kenneth Allen | Chief Financial Officer | 400600 0.3556% | $26.26 | 1 | 27 | <0.0001% |
Hamilton James C | Chief Discovery/Trans Medicine | 204851 0.1702% | $26.26 | 0 | 12 | |
San Martin Javier | Chief Medical Officer | 198497 0.1602% | $26.26 | 0 | 5 | |
Oliver Tracie | Chief Commercial Officer | 136501 0.1102% | $26.26 | 0 | 2 | |
GIVEN DOUGLAS B | director | 129711 0.1047% | $26.26 | 1 | 19 | <0.0001% |
Ferrari Mauro | director | 60778 0.0491% | $26.26 | 2 | 4 | +71% |
Waddill William D. | director | 47870 0.0386% | $26.26 | 0 | 7 | |
Lu Hongbo | director | 33680 0.0272% | $26.26 | 3 | 0 | |
Vakiener Victoria | director | 30205 0.0258% | $26.26 | 0 | 3 | |
GIVEN BRUCE D | Chief Operating Officer | 850730 0.6866% | $26.26 | 0 | 19 | |
Li Zhen | Snr. VP, Chem and Non-Clin Dev | 201700 0.1628% | $26.26 | 0 | 1 | |
KNOTT DAVID M | 10 percent owner | 166778 0.1346% | $26.26 | 1 | 3 | <0.0001% |
Leone Peter Brian | VP, Strategic Bus. Initiatives | 130000 0.1049% | $26.26 | 0 | 1 | |
Hassard James | Chief Commercial Officer | 105750 0.0854% | $26.26 | 0 | 2 | |
PERRY MICHAEL S | director | 85500 0.069% | $26.26 | 0 | 5 | |
FRYKMAN EDWARD W | director | 23852 0.0193% | $26.26 | 0 | 1 | |
McKenney Charles | director | 17220 0.0139% | $26.26 | 1 | 16 | |
De Backer Marianne | director | 17000 0.0137% | $26.26 | 9 | 2 | +50.28% |
Kingsley Joseph Theodore III | Interim President & CFO | 12000 0.0097% | $26.26 | 2 | 0 | +27.69% |
OLUKOTUN ADEOYE Y | director | 7867 0.0063% | $26.26 | 0 | 3 | |
Bradshaw Curt | Chief Scientific Officer | 0 0% | $26.26 | 0 | 2 | |
Lewis David L. | Chief Scientific Officer | 0 0% | $26.26 | 0 | 3 | |
Ching Marshall Robert | 10 percent owner | 0 0% | $26.26 | 0 | 6 |
BlackRock | $438.91M | 12.36 | 15.35M | +15.36% | +$58.43M | 0.01 | |
The Vanguard Group | $354.76M | 9.99 | 12.4M | +16.23% | +$49.53M | 0.01 | |
Avoro Capital Advisors Llc | $244.69M | 6.89 | 8.56M | +657.13% | +$212.37M | 2.93 | |
State Street | $187.64M | 5.28 | 6.56M | -3.87% | -$7.56M | 0.01 | |
Fidelity Investments | $182.89M | 5.15 | 6.39M | +89.68% | +$86.47M | 0.01 | |
Slate Path Capital LP | $118.38M | 3.33 | 4.14M | +211.44% | +$80.37M | 2.36 | |
Artal Group S A | $86.85M | 2.45 | 3.04M | +195.32% | +$57.44M | 0.46 | |
Geode Capital Management | $78.79M | 2.22 | 2.75M | +18.38% | +$12.24M | 0.01 | |
JPMorgan Chase | $75.45M | 2.12 | 2.64M | -4.11% | -$3.23M | 0.01 | |
T Rowe Price Investment Management Inc | $50.3M | 1.42 | 1.76M | New | +$50.3M | 0.03 | |
Credit Suisse | $46.52M | 1.31 | 1.63M | -6.81% | -$3.4M | 0.04 | |
Northern Trust | $37.2M | 1.05 | 1.3M | +5.78% | +$2.03M | 0.01 | |
Rokos Capital Management | $35.15M | 0.99 | 1.23M | 0% | +$0 | 0.92 | |
Morgan Stanley | $32.49M | 0.92 | 1.14M | +26.28% | +$6.76M | <0.01 | |
BNY Mellon | $30.17M | 0.85 | 1.05M | +10.13% | +$2.78M | 0.01 | |
Goldman Sachs | $30.02M | 0.85 | 1.05M | -1.17% | -$355,440.79 | 0.01 | |
Ameriprise Financial | $28.52M | 0.8 | 997,297 | +7.4% | +$1.96M | 0.01 | |
Charles Schwab | $28.14M | 0.79 | 983,755 | +16.29% | +$3.94M | 0.01 | |
Ubs Asset Management Americas Inc | $26.71M | 0.75 | 933,900 | -1.83% | -$497,468.40 | 0.01 | |
Spyglass Capital Management LLC | $25.98M | 0.73 | 908,474 | 0% | +$0 | 19.47 | |
Western Financial Corp Ca | $23.46M | 0.66 | 820,239 | 0% | +$0 | 14.79 | |
Citadel Advisors LLC | $21.22M | 0.6 | 741,897 | +1,165.24% | +$19.54M | 0.01 | |
OrbiMed | $21.15M | 0.6 | 739,651 | +131.39% | +$12.01M | 0.43 | |
Woodline Partners LP | $15.89M | 0.45 | 555,628 | -40.07% | -$10.63M | 0.15 | |
Capital International Investors | $13.7M | 0.39 | 479,106 | -62.5% | -$22.84M | <0.01 | |
Bank of America | $13.18M | 0.37 | 460,770 | -21.32% | -$3.57M | <0.01 | |
UBS | $12.9M | 0.36 | 450,921 | -11.34% | -$1.65M | <0.01 | |
Schonfeld Group | $11.89M | 0.34 | 415,783 | -9.67% | -$1.27M | 0.08 | |
RhumbLine Advisers | $10.64M | 0.3 | 372,105 | +15.43% | +$1.42M | 0.01 | |
Susquehanna International Group | $10.28M | 0.29 | 359,470 | +329% | +$7.88M | 0.01 | |
Retirement Systems of Alabama | $9.98M | 0.28 | 348,784 | +6.51% | +$610,066.58 | 0.04 | |
Assenagon Asset Management S.A. | $9.85M | 0.28 | 344,467 | +796.86% | +$8.75M | 0.03 | |
Nuveen | $9.38M | 0.26 | 328,033 | -4.78% | -$471,070.61 | <0.01 | |
Mirae Asset Global Investments Co Ltd | $8M | 0.26 | 327,782 | +67.25% | +$3.22M | 0.01 | |
Millennium Management LLC | $9.35M | 0.26 | 326,971 | New | +$9.35M | 0.01 | |
Eventide Asset Management | $8.96M | 0.25 | 313,289 | 0% | +$0 | 0.14 | |
Citigroup | $8.04M | 0.23 | 280,984 | +50.3% | +$2.69M | 0.01 | |
Rafferty Asset Management Llc | $7.84M | 0.22 | 274,159 | -24.91% | -$2.6M | 0.02 | |
Legal & General | $7.84M | 0.22 | 274,050 | -0.58% | -$45,388.19 | <0.01 | |
Privium Fund Management | $7.83M | 0.22 | 273,936 | 0% | +$0 | 2.29 | |
Invesco | $7.27M | 0.21 | 254,240 | -88.98% | -$58.69M | <0.01 | |
Octagon Capital Advisors LP | $7.15M | 0.2 | 250,000 | New | +$7.15M | 0.94 | |
Johnson & Johnson | $7.08M | 0.2 | 247,598 | 0% | +$0 | 0.16 | |
Swiss National Bank | $6.96M | 0.2 | 243,300 | +21.23% | +$1.22M | 0.01 | |
AllianceBernstein | $6.97M | 0.2 | 243,853 | +8.03% | +$518,460.82 | <0.01 | |
Russell Investments Group Ltd | $6.94M | 0.2 | 242,636 | -2.09% | -$148,176.97 | 0.01 | |
Deutsche Bank | $6.65M | 0.19 | 232,451 | -4.02% | -$278,278.02 | <0.01 | |
Candriam S C A | $6.52M | 0.18 | 228,054 | +23.24% | +$1.23M | 0.04 | |
WCM Investment Management | $6.45M | 0.18 | 225,583 | +30.5% | +$1.51M | 0.02 | |
Barclays | $6.38M | 0.18 | 223,148 | -38.35% | -$3.97M | <0.01 |